Maze Therapeutics (MAZE) Income from Continuing Operations (2024 - 2026)
Maze Therapeutics (MAZE) posted Income from Continuing Operations of 19595000.0 for Q1 2026, down 178.62% sequentially from 7033000.0 in Q4 2025, and up 40.23% YoY from 13973109.82 in Q1 2025.
Maze Therapeutics (MAZE) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Income from Continuing Operations for 3 years, with the latest figure at 19595000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 40.23% year-over-year to 19595000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 90394000.0 (down 315.65% YoY) and the FY2025 annual result came in at 103585000.0, down 345.53% from the prior year.
- Income from Continuing Operations retreated to 19595000.0 in Q1 2026 per MAZE's latest filing, from 7033000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 139056000.0 in Q2 2024 and troughed at 39622000.0 in Q4 2024.
- A 3-year average of 8467777.78 and a median of 27733000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 82.25% in 2025, down 124.22% in 2025.
- Over 3 years, Income from Continuing Operations stood at 39622000.0 in 2024, then soared by 82.25% to 7033000.0 in 2025, then slumped by 178.62% to 19595000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 19595000.0, 7033000.0, and 30087000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | -40.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.18 Mn |
| Mar 31, 2026 | -19.60 Mn |
| Dec 31, 2025 | -7.03 Mn |
| Sep 30, 2025 | -30.09 Mn |
| Jun 30, 2025 | -33.68 Mn |
| Mar 31, 2025 | -32.79 Mn |
| Dec 31, 2024 | -39.62 Mn |
| Sep 30, 2024 | -24.73 Mn |
| Jun 30, 2024 | 139.06 Mn |
| Mar 31, 2024 | -27.73 Mn |